This was posted at jrse.com under NEWS
JACOBSON RESONANCE ENTERPRISES, INC. QUARTERLY REPORT TO SHAREHOLDERS Quarter Ending September 30, 1998
Boca Raton, Florida. FINANCIALS Net loss for the nine months ending September 30, 1998 was $716,933 (or $.02 per share). The loss was primarily due to increased research and development expenses as the Company continued to expand its R&D capabilities. Cash balances were $753,514 as of September 30, 1998. The Company has included as part of this mailing a copy of our audited financial statements for the Years Ended December 31, 1997 and 1996.
RECENT DEVELOPMENTS The Company is pleased to announce that Robert Foreman, Professor and Chairman of Physiology at the University of Oklahoma Health Sciences Center, has accepted a Jacobson Resonator to utilize for studies on the quantification of pain. The Resonator was received by William Yamanashi, Professor of Medicine, and a member of our Scientific Advisory Board. The animal protocol for the pain study has been approved by the Institutional Animal Care and Use Committee (IACUC). A study is also planned by Professor Benjamin Sherlag, Director, and Professor Yamanashi at the University of Oklahoma's Cardiology Laboratory. Pico tesla range magnetic fields were calculated with Dr. Jerry Jacobson's mathematical formula. The objective is to examine the possibility of tracking the heart rate non-invasively.
Confirmations of earlier reported nerve regeneration studies at Cornell University School of Medicine are worthy of acknowledgement. Indeed, usage of Jacobson Resonance in treating mouse sciatic nerve sections showed regeneration, and maintained the integrity of cells and sub-cellular structures. The myelin sheaths appeared to grow and experienced repair in these studies executed by Brij Saxena, Professor of Endocrinology and Biochemistry. Human neuronal cells taken at autopsy from the brain have also shown stimulation when exposed to Jacobson Resonance fields in vitro. These studies are ongoing. Professor Saxena and Dr. Jacobson are currently preparing the nerve regeneration data for submission to Nature.
"We will attempt to fuse underpinning mechanisms in biochemical, physical and biological terms," Dr. Jacobson said at a recent conference in Marbella, Spain. "With the ongoing double-blind clinical trials (osteoarthritis and epilepsy) for FDA consideration, in additional to our rigorous investigations from the point of view of basic science, we hope to promulgate an explanation of how electromagnetic fields influence living systems (in terms of the underpinning mechanisms, which ensure understanding and replicability - the cornerstones of modern science)".
Double blind studies for the FDA in knee osteoarthritis are nearing completion at two sites, and are now being planned at a third site. About one hundred chronic sufferers have already been treated.
Texas A&M University has received a Jacobson Resonator and is preparing to execute studies to examine the potential for enhanced growth of vegetables with resonated water.
The Company has conducted high level discussions with a group of professional athletes and investors interested in distribution and marketing of a new portable Jacobson Resonator on a national basis.
With the assistance of Mr. Alfonso Serrato (a member of the Company's Board of Directors), Jacobson Resonance Enterprises, Inc. is pursuing a CE Mark (the European equivalent of FDA). The hope is to soon be manufacturing and distributing resonators in Europe.
On the financial front, the Company's new private placement of restricted common shares has successfully passed the minimum offering of $700,000. The Company anticipates closing this offering during the last quarter of this year. The monies received should allow the company to proceed with its ongoing research and development activities for much of 1999.
Finally, on July 28,1998 the Company's name was changed from Pioneer Services International, Ltd. to: Jacobson Resonance Enterprises, Inc. (OTC-BB-JRSE) with a new trade symbol of JRSE. The name change was done to better reflect the nature of the activities, technology, and services which are being performed by the Company .The company's informational web site has also changed and is now accessible on the internet at http: www.JRSE.com.
Sincerely,
Dr. Jerry I. Jacobson Chairman, President, CEO
Boca Raton, Florida (561) 477-8020 |
